CONFERENCE DAY ONE
FEBRUARY 18, 2025
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and hyper-relevant partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format, to find you your next partner and route to more capital.
9.15-9.45: The Need in Neuroscience: Activity & Ambition for Deal Making during the Neuroscience Resurgence from
the Pharma Icebreaker
9.45- 11.00: Face-to-face matchmaking for protected networking time during the Pharma Matchmaking Roundtables to
qualify, hear feedback, and generate interest for the rest of the conference
11.45-12.15: Differences across investor strategies when evaluating early stage developments
7.30 am One-on-One PartneringTM portal meeting schedule starts. Grab a coffee and sit down with key contacts in the hour before the conference at bookable meeting spaces.
8:30 am Chair’s Opening Remarks
Strategic Priorities & Deal Trends for Future Collaborations & Investment in Neuroscience
8:40 am Pharma Icebreaker: The Need in Neuroscience: Activity & Ambition for Deal Making during the Neuroscience Resurgence
Synopsis
- Sharing recent deal-making, current search and evaluation interests, and what pharma is looking for as a backdrop for conversations ahead
- Discussing where future deal-making will lie for neurodegeneration and psychiatry distinctly to give insight into the before and landscape evolution
9:15 am Pharma Matchmaking Roundtables: Ensure you Connect
Synopsis
For interested parties, both pharma and attending biotech can select companies of interest for pre-organized rotations of 15-minute meetings across 1 hour. Meet face-to-face with priority companies, and benefit from introducing yourself to pharma you have not scheduled meetings with through the One-on-One PartneringTM portal early in the event.
10:45 pm Morning Break & One-on-One Networking
11:45 am Venture Panel:What Data Package is Exciting Enough to Invest in?
Synopsis
- Where is each fund’s focus in Neuroscience? What is each fund excited about going forward regarding data or company type?
- What does the panel see as newer and more interesting differentiation points?
- When it comes to early innovation, what does the panel need to see to be excited about investing?
12:15 pm Lunch Break & One-on-One Partnering Networking
PART TWO: SHOWCASE YOUR SCIENCE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase your
pipeline, platform, and technologies to a room of aligned and qualified decision-makers.
Section One: The Right Modality for the Right Disease Marrying Breakthrough in Modalities with Breakthrough in Delivery, for Greater Duration of Action
1:20 pm Using the iNeuroRx® Technology Platform to Develop Disease-Modifying Treatments for ALS & FTD
Synopsis
- Introducing the iNeuroRx® platform as the most genetically diverse ALS / FTD disease platform capable of modeling heterogeneity in the patient population
- Detailing how the iNeuroRx® platform provides for the identification of the most potent, durable and safe antisense oligonucleotide (ASO) drug candidates
- Sharing AcuraStem’s three ASO programs in development targeting UNC13A, SYF2 and PIKFYVE (partnered with Takeda)
- Highlighting the use of the platform to understand how
1:40 pm Leveraging the Power of Biotherapeutics to Address Unmet Medical Needs in CNS Diseases
Synopsis
- Evidencing how significant progress in the understanding of the biology of the bloodbrain-barrier has enabled biologics to become a viable modality for CNS diseases
- Augmenting therapeutic efficacy of 2nd generation of approved Biologics Safe, through effective CNS shuttle platforms
- Outlining key differences that exist in the delivery of protein therapeutics versus nucleic acid medicine into the brain
14:00 pm Afternoon Break & One-on-One Partnering Networking
3:40 pm Next Generation Splice Modulation Platform: Balancing Activity, Safety & Distribution of ASOs
Synopsis
- Contextualizing preRNA mis-splicing as a recurring theme in neurodegenerative diseases
- Highlighting QurAlis’ FlexASO™ platform that enables the design and synthesis of splice-switching ASOs with enhanced potency, safety, and biodistribution properties
- Discussing the platform generally and in the context of QurAlis’ discovery programs
4:00 pm Building on Clinical Progress & Challenges of PROTACs with Molecular Glues
Synopsis
- Improving drug-like properties to drive efficacy
- Increasing specificity of degradation and avoiding neo-substrate degradation
- Increasing the cell type and tissue reach of degraders
4:20 pm M102, a Combined NRF2 & HSF-1 Activator for Neuroprotection in ALS & Other Neurodegenerative Diseases, Now Heading into the Clinic
Synopsis
- Introducing M102, a dual NRF2/HSF1 activator, targeting redox imbalance, inflammation, mitochondrial dysfunction and altered proteostasis, that has been shown to slow disease and potentially stop progression in a TDP43 model; entering Phase 1 trials in ALS in Q1 2025
- Discussing Aclipse’s comprehensive biomarker strategy, including potential patient stratification biomarkers using a proprietary ALS patient-derived iAstrocyte survival model
- Outlining the Aclipse search-evaluate-invest-develop model, to initiate outreach to potential partners
4:40 pm Targeting Tumor Regulators in Pediatric High-Risk Neural Tumors (PHRNT), A Novel Small Molecule Approach to MYC-N Amplified Pediatric Cancers
Synopsis
- Novel small molecule therapy targeting tumor regulators in pediatric high-risk neural tumors (PHRNT), focusing on MYC-N amplified cancers.
- Cutting-edge approach that disrupts oncogenic pathways and restores protein homeostasis, offering a breakthrough treatment for pediatric cancers.
- Addressing a critical unmet need in pediatric oncology with the potential to reshape treatment paradigms and significantly improve survival rates
5.00 Aperitif Drinks Reception:
Enjoy an informal networking drinks reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting, as a touchpoint between JPM and BIO in the conference calendar.